ATyr Provides Tentative FDA Timeline For Phase 3 Efzofitimod In Lung Disease

aTyr Pharma (ATYR) updated investors on the expected timing of a U.S. FDA response to its protocol for a planned Phase 3 study of efzofitimod in pulmonary sarcoidosis. The news is procedural/regulatory in nature and does not change trial efficacy or financial guidance directly, but it can influence near-term expectations for the Phase 3 path.